{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-018242","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2025-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.655783+00:00","generated_at":"2026-05-23T11:32:58.083558+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Madrigal CMO/President of R&D Rebecca Taub steps down, becomes Senior Advisor through Dec 2025","bullets":["Dr. Taub transitions from CMO and President of R&D to Senior Scientific and Medical Advisor effective April 21, 2025, through end of 2025.","She will continue to serve on Madrigal's Board of Directors.","Will receive base salary of $621,000 through Dec 31, 2025, and eligible for a 50% target bonus.","Entered a Severance and Change of Control Agreement with standard severance: 12-month salary continuation, equity acceleration, and health benefits.","No successor named; Taub will provide transition support and scientific guidance for MASH programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-018242","json":"https://secwatch.observer/filing/0001628280-25-018242.json","markdown":"https://secwatch.observer/filing/0001628280-25-018242.md","text":"https://secwatch.observer/filing/0001628280-25-018242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025018242/0001628280-25-018242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025018242/mdgl-20250416.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T11:32:58.083558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49f5595dd2","claim":"Rebecca Taub changed role as Senior Scientific and Medical Advisor at MADRIGAL PHARMACEUTICALS, INC..","evidence_excerpt":"Pursuant to the Letter Agreement, effective as of April 21, 2025, Dr. Taub will transition from her current role and responsibilities to a new role as a Senior Scientific and Medical Advisor to the Company through the end of 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025018242/0001628280-25-018242-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Senior Scientific and Medical Advisor"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}